iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh
Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.